SBIR-STTR Award

Antimicrobial Copper Alloy Coatings for Contact Environments
Award last edited on: 10/29/18

Sponsored Program
SBIR
Awarding Agency
NIH : NIBIB
Total Award Amount
$148,874
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Joshua Caris

Company Information

MesoCoat Inc (AKA: Mesocoat Advanced Coating Tech~Abakan)

24112 Rockwell Drive
Euclid, OH 44117
   (216) 453-0866
   info@mesocoat.com
   www.mesocoat.com
Location: Single
Congr. District: 11
County: 

Phase I

Contract Number: 1R43EB018150-01A1
Start Date: 9/22/14    Completed: 3/21/15
Phase I year
2014
Phase I Amount
$148,874
This Small Business Innovation Research Phase I project shows great intellectual merit. The antimicrobial properties of copper-based alloys continue to be a topic of research interest, and there are no current publications detailing the mechanical properties, corrosion resistance, and anti-microbial characteristics of copper-based alloy bi-layers. Pending a successful Phase I research program, high wear and corrosion-resistant copper alloys in the form of copper-based alloys will be evaluated. The broader impacts of this project are manifold. An inherently anti- bacterial coating for hospital applications has wide-ranging effects on degree of health care and mitigation of costs incurred through infection associated with hospital practice. Common examples include: infections from biomedical implants, degradation of protective coatings on buildings, fouling of food products, loss of efficacy of pharmaceutical formulations, and many more. A growing body of health literature is promoting the use of copper-based alloys for consumer applications, and copper alloy coatings on conventional steel substrates will prove viable, low cost alternatives to the current copper alloys in structural applications. MesoCoat is commercializing its CermaClad" high rate cladding process for the oil and gas and infrastructure industries, and this program will explore the extension of this technology into the antimicrobial surfaces (medical devices and indoor air quality) industry verticals via copper- cladding of steel substrates.

Public Health Relevance Statement:


Public Health Relevance:
An inherently anti-bacterial coating for hospital applications developed through this Phase I program has wide-ranging effects on degree of health care and mitigation of costs incurred through infection associated with hospital practice. In addition to hospitals, these coatings could also be applied to other public areas such as airports, bus stations, railway stations, schools, restaurants, work places, etc. Thus this research would have a significant impact on public health by improving health related quality of life by preventing or delaying the onset of disease.

Project Terms:
Address; Alloys; Anti-Bacterial Agents; antimicrobial; Antimicrobial Resistance; Appearance; Area; base; Behavior; Cereals; Characteristics; Chemicals; commercialization; Complex; Copper; Corrosion; cost; Data; Development; Dimensions; Drug Formulations; Environment; Evaluation; experience; Exposure to; Family; Film; Food; Future; Gases; Goals; Health; health related quality of life; Healthcare; Heating; Hospitals; implantable device; improved; Indoor Air Quality; Industry; Infection; interest; Life; Literature; Mechanics; Medical; Medical Device; Metals; Methods; nanoparticle; Oils; Onset of illness; operation; Output; Pharmacologic Substance; Phase; Porosity; prevent; Process; programs; Property; public health medicine (field); public health relevance; Publications; Research; Research Infrastructure; research study; Resistance; Restaurants; Risk; Risk Reduction; Sampling; scale up; Schools; screening; Series; Shapes; Simulate; Small Business Innovation Research Grant; Solutions; Spottings; Stainless Steel; Steel; Sterilization; Surface; surface coating; Surface Tension; Technology; technology development; Temperature; Touch sensation; Tube; Viscosity; Welding; Workplace

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----